Compare Stocks: NCNA, AYTU, PLRZ, and CLRB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.25	$2.23	$1.65 ▼ $3.07	$24.14M	0.25	30,781 shs	10,413 shs
CLRB Cellectar Biosciences	$2.53	$2.59	$2.20 ▼ $6.52	$23.91M	0.55	29,426 shs	23,826 shs
NCNA NuCana	$1.76	$1.43	$1.21 ▼ $7.22	$7.32M	2.25	83,556 shs	970,539 shs
PLRZ Polyrizon	$13.15	$12.35	$2.88 ▼ $18.20	$27.35M	-1.5	69,512 shs	96,403 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	-5.06%	+0.90%	+4.65%	-4.26%
CLRB Cellectar Biosciences	0.00%	-2.32%	-1.56%	-14.81%	-48.05%
NCNA NuCana	0.00%	+15.79%	+33.33%	-18.89%	-44.83%
PLRZ Polyrizon	0.00%	+27.67%	+16.89%	-14.67%	+101.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.25	$2.23	$1.65 ▼ $3.07	$24.14M	0.25	30,781 shs	10,413 shs
CLRB Cellectar Biosciences	$2.53	$2.59	$2.20 ▼ $6.52	$23.91M	0.55	29,426 shs	23,826 shs
NCNA NuCana	$1.76	$1.43	$1.21 ▼ $7.22	$7.32M	2.25	83,556 shs	970,539 shs
PLRZ Polyrizon	$13.15	$12.35	$2.88 ▼ $18.20	$27.35M	-1.5	69,512 shs	96,403 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	-5.06%	+0.90%	+4.65%	-4.26%
CLRB Cellectar Biosciences	0.00%	-2.32%	-1.56%	-14.81%	-48.05%
NCNA NuCana	0.00%	+15.79%	+33.33%	-18.89%	-44.83%
PLRZ Polyrizon	0.00%	+27.67%	+16.89%	-14.67%	+101.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	2.25	Hold	$10.75	377.78% Upside
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	334.78% Upside
NCNA NuCana	1.00	Sell	N/A	N/A
PLRZ Polyrizon	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest NCNA, AYTU, PLRZ, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/14/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CLRB Cellectar Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	NCNA NuCana	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	AYTU Aytu BioPharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/12/2026	CLRB Cellectar Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/6/2026	AYTU Aytu BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/11/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$66.38M	0.36	$0.38 per share	5.99	$2.11 per share	1.07
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	$7.71 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$13.56M	-$4.58	N/A	9.00	N/A	-60.17%	-69.93%	-13.25%	9/29/2026 (Estimated)
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
NCNA NuCana	-$38.71M	-$3.81	N/A	N/A	N/A	N/A	-41.90%	-33.69%	11/12/2026 (Estimated)
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest NCNA, AYTU, PLRZ, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/22/2026	Q4 2026	AYTU Aytu BioPharma	-$0.22	N/A	N/A	N/A	$17.18 million	N/A
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	NCNA NuCana	-$2.6514	-$0.99	+$1.6614	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.12	1.00
CLRB Cellectar Biosciences	N/A	6.66	6.66
NCNA NuCana	N/A	4.73	4.73
PLRZ Polyrizon	N/A	29.03	29.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
CLRB Cellectar Biosciences	16.41%
NCNA NuCana	44.00%
PLRZ Polyrizon	N/A

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	4.90%
CLRB Cellectar Biosciences	2.58%
NCNA NuCana	31.20%
PLRZ Polyrizon	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	10.73 million	10.21 million	Not Optionable
CLRB Cellectar Biosciences	10	9.45 million	9.21 million	No Data
NCNA NuCana	30	4.16 million	2.86 million	Not Optionable
PLRZ Polyrizon	N/A	2.08 million	N/A	N/A

NCNA, AYTU, PLRZ, and CLRB Headlines

Recent News About These Companies

Polyrizon Finalizes U.S. Clinical Site Network for NASARIX Allergy Study

August 20, 2026 | tipranks.com

Polyrizon Completes Site Contracting for NASARIX™ Seasonal Allergic Rhinitis Study

August 20, 2026 | quiverquant.comQ

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

August 20, 2026 | globenewswire.com

Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026

July 13, 2026 | tipranks.com

Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray

July 2, 2026 | tipranks.com

Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)

July 2, 2026 | msn.com

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting ...

July 2, 2026 | enidnews.comE

Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray

July 2, 2026 | quiverquant.comQ

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

July 2, 2026 | globenewswire.com

Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial

June 29, 2026 | tipranks.com

Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker

June 29, 2026 | quiverquant.comQ

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial

June 29, 2026 | globenewswire.com

Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent

June 17, 2026 | tipranks.com

Polyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

June 17, 2026 | finanznachrichten.de

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

June 17, 2026 | globenewswire.com

Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway

June 15, 2026 | tipranks.com

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

June 15, 2026 | globenewswire.com

Polyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology

June 12, 2026 | finanznachrichten.de

Polyrizon Marches on European Patent

June 11, 2026 | baystreet.ca

Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform

June 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA, AYTU, PLRZ, and CLRB Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.25 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.26 +0.00 (+0.22%)

As of 03:59 AM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Cellectar Biosciences NASDAQ:CLRB

$2.53 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.67 +0.14 (+5.53%)

As of 04:53 AM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

NuCana NASDAQ:NCNA

$1.76 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.55 -0.21 (-11.88%)

As of 05:00 AM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Polyrizon NASDAQ:PLRZ

$13.15 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$12.99 -0.16 (-1.21%)

As of 04:11 AM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NCNA, AYTU, PLRZ, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NCNA, AYTU, PLRZ, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NCNA, AYTU, PLRZ, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA, AYTU, PLRZ, and CLRB Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Cellectar Biosciences NASDAQ:CLRB

NuCana NASDAQ:NCNA

Polyrizon NASDAQ:PLRZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NCNA, AYTU, PLRZ, and CLRB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NCNA, AYTU, PLRZ, and CLRB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NCNA, AYTU, PLRZ, and CLRB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA, AYTU, PLRZ, and CLRB Company Descriptions

Aytu BioPharma NASDAQ:AYTU

Cellectar Biosciences NASDAQ:CLRB

NuCana NASDAQ:NCNA

Polyrizon NASDAQ:PLRZ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools